Vertex Pharmaceuticals/ US92532F1003 /
| 2024-04-16 9:59:58 PM | Chg. -3.37 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 394.11USD | -0.85% | 25,913 Turnover: 10.24 mill. |
-Bid Size: - | -Ask Size: - | 101.82 bill.USD | - | 28.05 |
Assets
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 758.0850 | 958.5340 | 1,094.1000 | 1,108.4000 | 1,159.3000 | ||||||
| Intangible Assets | 400 | 400 | 400 | 603.6000 | 839.9000 | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | 3,495.6360 | 3,618.4290 | 3,871.9000 | 4,916.1000 | 8,586 | ||||||
| Inventories | 167.5020 | 280.7770 | 353.1000 | 460.6000 | 738.8000 | ||||||
| Accounts Receivable | 633.5180 | 885.3520 | 1,136.8000 | 1,442.2000 | 1,563.4000 | ||||||
| Cash and Cash Equivalents | 3,109.3220 | 5,988.1870 | 6,795 | 10,504 | 10,369.1000 | ||||||
| Current Assets | 4,822.8290 | 8,133.3790 | 9,560.6000 | 13,234.8000 | 14,144.2000 | ||||||
| Total Assets | 8,318.4650 | 11,751.8080 | 13,432.5000 | 18,150.9000 | 22,730.2000 | ||||||
Liabilities
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 87.6100 | 155.1390 | 195 | 303.9000 | 364.9000 | ||||||
| Long-term debt | 538.5760 | 539.0420 | 509.8000 | 430.8000 | 376.1000 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 2,233.2210 | 3,064.9930 | 3,332.5000 | 4,238.2000 | 5,149.8000 | ||||||
| Share Capital | 2.5890 | 2.5990 | 2.5000 | 2.6000 | 2.6000 | ||||||
| Total Equity | 6,085.2440 | 8,686.8150 | 10,100 | 13,912.7000 | 17,580.4000 | ||||||
| Minority Interests | 0.0000 | 0.0000 | - | - | - | ||||||
| Total liabilities equity | 8,318.4650 | 11,751.8080 | 13,432.5000 | 18,150.9000 | 22,730.2000 | ||||||
Income Statement
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 4,162.8210 | 6,205.6830 | 7,574.4000 | 8,930.7000 | 9,869.2000 | ||||||
| Depreciation (total) | 106.9410 | 109.5150 | 125.6000 | 148.3000 | 181.3000 | ||||||
| Operating Result | 1,197.5660 | 2,856.2900 | 2,782.1000 | 4,307.4000 | 3,832 | ||||||
| Interest Income | - | - | 61.5000 | 54.8000 | 44.1000 | ||||||
| Income Before Taxes | 1,394.9190 | 3,116.7980 | 2,730.4000 | 4,232.4000 | 4,379.8000 | ||||||
| Income Taxes | 218.1090 | 405.1510 | 388.3000 | 910.4000 | 760.2000 | ||||||
| Minority Interests Profit | 0.0000 | 0.0000 | - | - | - | ||||||
| Net Income | 1,176.8100 | 2,711.6470 | 2,342.1000 | 3,322 | 3,619.6000 | ||||||
Per Share
Cash Flow
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 1,569.3300 | 3,253.5050 | 2,643.5000 | 4,129.9000 | 3,537.3000 | ||||||
| Cash Flow from Investing Activities | -1,235.3180 | 99.3880 | -340.9000 | -321.1000 | -3,141.7000 | ||||||
| Cash Flow from Financing | 126.7730 | -505.2810 | -1,478 | -67.7000 | -562.2000 | ||||||
| Decrease / Increase in Cash | 462.4280 | 2,868.1640 | 811.2000 | 3,711.9000 | -139.7000 | ||||||
| Employees | 3,000 | 3,400 | 3,900 | - | - | ||||||
